Gemcitabine was chosen to be combined with the anti-PD-L1 monoclonal antibody pembrolizumab, as some immunogenic properties through the elimination of myeloid-derived suppressor cells (MDSCs) and lymphocytes T regulators (Tregs) in preclinical tumor models were previously suggested [6,7,8,9]. The gene discussed is CD274; the disease is neoplasm.